• Disclosure
  • Privacy Policy
  • DMCA Policy
  • CCPA
  • Medical Disclaimer
Monday, March 27, 2023
SLC Metro News
  • Home
  • News
  • Business
  • Technology
    • Crytpocurrency
    • Gaming
    • Gadgets
  • Sports
  • Health
  • General
    • Business Services
  • Travel
  • Press Releases
  • Popular
No Result
View All Result
  • Home
  • News
  • Business
  • Technology
    • Crytpocurrency
    • Gaming
    • Gadgets
  • Sports
  • Health
  • General
    • Business Services
  • Travel
  • Press Releases
  • Popular
No Result
View All Result
No Result
View All Result
Home Technology Gaming

Stock Market News Live Updates: Stocks Mixed After Two-Day Rally Amid Pfizer’s Omicron Vaccine Update – Yahoo Finance

stock-market-news-live-updates:-stocks-mixed-after-two-day-rally-amid-pfizer’s-omicron-vaccine-update-–-yahoo-finance
Share on FacebookShare on Twitter

Stocks traded mixed to pause after a two-day rally, as investors further considered updates around the Omicron variant and weighed a potential policy pivot by the Federal Reserve. 

A day earlier, technology stocks outperformed to pull the Nasdaq higher by more than 3%, in its best day since March. As of Tuesday’s close, the S&P 500 was less than 0.5% below its levels from Nov. 24, or the session before the World Health Organization’s announcement of the Omicron’s discovery.

Treasury yields steadied after a jump on Tuesday, and the yield on the 10-year Treasury note traded just below 1.5%. U.S. West Texas intermediate crude oil futures hovered around $71 per barrel, while Bitcoin slipped back near $50,000. 

Investors have snapped up risk assets so far this week amid prospects that the Omicron variant may not pose as severe a health threat as previously feared. And elsewhere, the latest developments in Washington, D.C., indicated lawmakers were on track to raise the debt-ceiling before a Dec. 15 deadline, which if not extended would leave the U.S. Treasury without sufficient funds to repay U.S. debt holders. The House of Representatives voted Tuesday night to approve a bill paving the way for Senate lawmakers to raise the limit with a simple majority vote.

Pfizer (PFE) shares traded slightly higher after the company said that three doses of its Pfizer-BioNTech (BNTX) vaccine “neutralize” the Omicron variant, while noting that two doses “may not be sufficient to protect against infection” with Omicron. Other recent developments around the virus have also been upbeat, with Dr. Anthony Fauci telling the AFP on Tuesday that Omicron infections are “almost certainly” not more severe than those caused by the previous Delta variant. 

“Economic growth is going to be strong. Certainly the Omicron variant could possibly push some of that out, but it won’t eliminate it given the underlying fundamentals,” Brent Schutte, chief investment strategist for Northwestern Mutual, told Yahoo Finance Live. “And the Federal Reserve certainly will focus a bit more on tapering — that kind of spooked the market — but ask yourself: What impact is that going to have on growth? The answer to us is not much. You are still going to have a strong U.S. economy next year on the back of reopening, on the back of all the cash that is still available on the consumer balance sheet.” 

Other strategists echoed these sentiments. 

“We do think that there is fundamental support there for markets to continue to move higher here,” Emily Roland, co-chief investment strategist at John Hancock investment management, told Yahoo Finance Live on Tuesday. “Obviously we had a couple of things spook us over the last week or so, the emergence of the Omicron variant as well as this pivot from the Fed, potentially seeing them accelerating their tapering of asset purchases here. But the bottom line is that the economy is strong.” 

“So until it looks like we’re inching closer to a recession here, which we’re nowhere near at this point, it’s hard for us to get too defensive,” she added. “We continue to embrace equities, we like the U.S. the most, that’s where we’re seeing the best relative economic growth, that’s where we’re seeing the best relative earnings growth. And again, the other element here is that there is a ton of cash on the sidelines that’s looking to get put to work.” 

—

4:09 p.m. ET: Stocks eke out third straight day of gains after Pfizer says third dose of vaccine neutralizes Omicron

Here were the main moves in markets as of 4:09 p.m. ET:

  • S&P 500 (^GSPC): +14.46 (+0.31%) to 4,701.21

  • Dow (^DJI): +35.32 (+0.10%) to 35,754.75

  • Nasdaq (^IXIC): +100.07 (+0.64%) to 15,786.99

  • Crude (CL=F): +$0.54 (+0.75%) to $72.59 a barrel

  • Gold (GC=F): +$2.10 (+0.12%) to $1,786.80 per ounce

  • 10-year Treasury (^TNX): +2.9 bps to yield 1.5090%

—

11:11 a.m. ET: Crude oil inventories dropped less than expectedT last week: EIA

The Energy Information Administration said in its weekly report Wednesday that U.S. crude oil inventories dropped by 241,000 barrels last week. 

The sum was much less pronounced than the drop of 1.521 million barrels consensus economists were expecting, based on Bloomberg data. The weekly report also spotlighted that crude imports fell by 105,000 barrels per day, while crude production increased by 100,000 barrels per day. 

U.S. West Texas intermediate crude oil futures ticked down by about 0.3% Wednesday morning, to give back some gains after jumping by 3.7% on. Tuesday and 4.9% on Monday. Brent crude oil futures, the international benchmark, edged lower by about the same margin to hover above $75 per barrel. 

—

10:00 a.m. ET: Job openings climb to near-record high in October

Job openings in the U.S. jumped by a greater-than-expected margin in October, underscoring the still-widespread mismatches in labor supply and demand as shortages abound.

The Labor Department said Wednesday that U.S. job openings totaled 11.033 million in October, coming in above consensus economists’ expectations for 10.469 million, according to Bloomberg data. Job openings in September were upwardly revised to 10.602 million, from the 10.438 million previously reported.

The quits rate came down only slightly in October to reach 2.8%, versus September’s all-time high of 3.0%. 

—

9:30 a.m. ET: Stocks open higher amid Pfizer vaccine news

Stocks traded mixed and came off the highs of the overnight session as investors continued to digest new updates on Pfizer’s COVID-19 vaccine and its efficacy against the Omicron variant. 

The Dow traded higher by more than 100 points, or 0.3%. The S&P 500 was little changed, while the Nasdaq dropped 0.2%. 

Small-cap stocks continued to jump, with the Russell 2000 index up another more than 2%. 

—

7:32 a.m. ET Wednesday: Stocks head for third straight session of gains

Here’s where markets were trading ahead of opening bell:

  • S&P 500 futures (ES=F): +13.5 points (+0.29%), to 4,698.50

  • Dow futures (YM=F): +114.00 points (+0.32%), to 35,827.00

  • Nasdaq futures (NQ=F): +39.75 points (+0.24%) to 16,357.75

  • Crude (CL=F): -$0.01 (-0.01%) to $72.04 a barrel

  • Gold (GC=F): +$1.00 (+0.06%) to $1,785.70 per ounce

  • 10-year Treasury (^TNX): -0.8 bps to yield 1.472%

—

6:06 p.m. ET Tuesday: Stock futures open higher after rally 

Here were the main moves in markets in late trading on Tuesday:

  • S&P 500 futures (ES=F): +3 points (+0.06%), to 4,688.00

  • Dow futures (YM=F): +9 points (+0.03%), to 35,722.00

  • Nasdaq futures (NQ=F): +21.5 points (+0.13%) to 16,339.5

NEW YORK, NEW YORK - DECEMBER 02: Traders work on the floor of the New York Stock Exchange (NYSE) on December 02, 2021 in New York City. The Dow rose over 500 points today after falling yesterday due to fears of the omicron strain of the Covid-19 virus.  (Photo by Spencer Platt/Getty Images)

NEW YORK, NEW YORK – DECEMBER 02: Traders work on the floor of the New York Stock Exchange (NYSE) on December 02, 2021 in New York City. The Dow rose over 500 points today after falling yesterday due to fears of the omicron strain of the Covid-19 virus. (Photo by Spencer Platt/Getty Images)

—

Emily McCormick is a reporter for Yahoo Finance. Follow her on Twitter

3921e250 d456 11eb b8f6 884493f3555b

SLC Metro News

© 2021 SLC Metro News

Navigate Site

  • Disclosure
  • Privacy Policy
  • DMCA Policy
  • CCPA
  • Medical Disclaimer

Follow Us

No Result
View All Result
  • Home
  • DMCA Policy
  • Medical Disclaimer
  • Privacy Policy
  • Disclosure
  • CCPA
  • Terms of Use

© 2021 SLC Metro News

We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept All”, you consent to the use of ALL the cookies. However, you may visit "Cookie Settings" to provide a controlled consent.
Cookie SettingsAccept All
Manage consent

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. These cookies ensure basic functionalities and security features of the website, anonymously.
CookieDurationDescription
cookielawinfo-checkbox-analytics11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-functional11 monthsThe cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-others11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-performance11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
viewed_cookie_policy11 monthsThe cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
Functional
Functional cookies help to perform certain functionalities like sharing the content of the website on social media platforms, collect feedbacks, and other third-party features.
Performance
Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.
Analytics
Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics the number of visitors, bounce rate, traffic source, etc.
Advertisement
Advertisement cookies are used to provide visitors with relevant ads and marketing campaigns. These cookies track visitors across websites and collect information to provide customized ads.
Others
Other uncategorized cookies are those that are being analyzed and have not been classified into a category as yet.
SAVE & ACCEPT